Aura Biosciences, Inc. (AURA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
85 Bolton Street
Boston, MA 02140
United States of America (the)
Phone
617 500 8864
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Elisabet de los Pinos | Founder, Chief Executive Officer, President & Director | 950,496 | 1974 |
| Natalie C. Holles | President, CEO & Director | 0 | 1973 |
| Anthony S. Gibney | Chief Financial & Business Officer | 604,091 | 1971 |
| Conor Kilroy | Chief Legal Officer & Secretary | 611,162 | 1982 |
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 792,750 | 1965 |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | 0 | N/A |
| Mark Plavsic | Chief Technology Officer | 0 | 1961 |
| Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology | 0 | N/A |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | 0 | N/A |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | 0 | 1974 |
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.